Answers are grounded in this paper and cite their sources.
Evaluate the safety, tolerability, and pharmacokinetics of intranasal zavegepant—a third-generation, high-affinity, selective and structurally unique, small molecule calcitonin gene-related peptide receptor (CGRP) antagonist—after administration of ascending single and multiple doses in healthy fasted adults.
No takes yet. Share an insight, caveat, or question.
Bertz et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: